Proportions of patients meeting definitions for progressive disease or improvement should be included in clinical trials for systemic sclerosis interstitial lung disease

By afschroeder • April 15, 2026

Morrisroe K, Tashkin D, Baron M. Proportions of patients meeting definitions for progressive disease or improvement should be included in clinical trials for systemic sclerosis interstitial lung disease. Arthritis Res Ther. 2026 Apr 14;28(1):88. doi: 10.1186/s13075-026-03803-z. PMID: 41981638.

Tags: Publications, Pulmonary, Critical Care & Sleep Medicine

Inflammatory Eye Disease and Immunosuppressive Therapy: A Rheumatologist’s Perspective

Aung T. Inflammatory Eye Disease and Immunosuppressive Therapy: A Rheumatologist's Perspective. Cureus. 2026 Sep 24;18(9):e116847. doi: 10.7759/cureus.116847. PMID: 42927373; PMCID: PMC13695429.

Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label phase 3 LITESPARK-012 study

Rini BI, Choueiri TK, Voss MH, Burotto M, Oldenburg J, Gurney HP, Ferguson TR, Hammers H, Albiges L, Ürün Y, Romero Diaz RI, Özgüroğlu M,[...]

Caregiver Perspectives on Out-of-School-Time Activities and Resource Needs Among Families With Adverse Childhood Experiences: A Cross-Sectional Survey

La Charite J, Duong-Brett S, Reese C, Santoro M, Schickedanz A, Dudovitz R. Caregiver Perspectives on Out-of-School-Time Activities and Resource Needs Among Families With Adverse[...]